Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 2, 2012, Pages 175-179

  Li, Meng ^a   Liao, Yong ^b   Chen, Min ^a   Pan, Weihua ^a   Weng, Lixing ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NANJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Antifungal agents; Cryptococcus gattii; Cryptococcus neoformans

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CHINA; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DILUTION; FUNGUS ISOLATION; GENOTYPE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 85027949219     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70301-X     Document Type: Article

References (21)

1. Kwon-Chung K.J., Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans?. FEMS Yeast Res 2006, 6:574-587.
2. Mirza S.A., Phelan M., Rimland D., et al. The changing epidemiology of cryptococcosis: an update from populationbased active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789-794.
3. Chen M., Li X.R., Wu S.X., et al. Molecular epidemiology of Cryptococcus neoformans species complex isolates from HIV-positive and HIV-negative patients in southeast China. Frontiers of Medicine in China 2010, 4:117-126.
4. Yao Z., Liao W., Chen R. Management of cryptococcosis in non-HIV-related patients. Med Mycol 2005, 43:245-251.
5. Dromer F., Mathoulin-Pélissier S., Fontanet A., et al. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004, 18:555-562.
6. Iqbal N., DeBess E.E., Wohrle R., et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 2010, 48:539-544.
7. Chen Y.C., Chang S.C., Shih C.C., et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000, 36:175-183.
8. Zhu L.P., Gil-Lamaignere C., Müller F.M. Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China. Mycoses 2004, 47:319-325.
9. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2 2002, National Committee for Clinical Laboratory Standards, NCCLS, Wayne, PA, USA.
10. Datta K., Jain N., Sethi S., et al. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 2003, 52:683-686.
11. Tay S.T., Tanty Haryanty T., Ng K.P., et al. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 2006, 49:324-330.
12. Sar B., Monchy D., Vann M., et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004, 54:563-565.
13. Almeida A.M., Matsumoto M.T., Baeza L.C., et al. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil. FEMS Yeast Res 2007, 7:152-164.
14. Chandenier J., Adou-Bryn K.D., Douchet C., et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004, 23:506-508.
15. Pappalardo M.C., Szeszs M.W., Martins M.A., et al. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Diagn Microbiol Infect Dis 2009, 64:146-151.
16. Lozano-Chiu M., Paetznick V.L., Ghannoum M.A., Rex J.H. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998, 36:2817-2822.
17. Perkins A., Gomez-Lopez A., Mellado E., Rodriguez-Tudela J.L., Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005, 56:144-147.
18. Morgan J., McCarthy K.M., Gould S., et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006, 43:1077-1080.
19. Gomez-Lopez A., Zaragoza O., Dos Anjos Martins M., et al. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 2008, 14:727-730.
20. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
21. Hardiman R.P., Marriott D.J., Chen S., et al. The development of amphotericin B resistant Cryptococcus neoformans during treatment of cryptococcal meningitis in an HIV-infected patient. Annu Conf Australas Soc HIV Med 1996, 8:14-17.